Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Rejects Illumina Acquisition Of Grail

Executive Summary

The European Union’s antitrust commission blocked the re-acquisition of Grail by Illumina days after an FTC administrative law judge ruled in favor of the merger in the US.

You may also be interested in...

BioBytes: Against A Turbulent Corporate Backdrop, Illumina Touts New AI Gene Analysis Tool

Welcome to In Vivo’s new AI-focused blog, BioBytes, providing news and insight on the growing role of artificial intelligence in biopharma. In this post, Illumina’s new large language model-based gene analysis tool could help drive uptake of its products.

Illumina Appeals FTC Decision, Grail Swings And Misses

Illumina has formally appealed the FTC’s decision to block its acquisition of Grail, just days after Grail mistakenly sent letters to patients suggesting they could have cancer.

Illumina Claps Back At Carl Icahn

Carl Icahn has been causing trouble at the sequencing giant, using its muddied merger with Grail as justification for the nomination of three new board members of his choosing.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts